Actively Recruiting
Phase 2 Study of RC48-ADC Intravenous and Gemcitabine Bladder Instillation in Adults with High-Risk Non-Muscle-Invasive Bladder Cancer Who Are BCG Naive or BCG Unresponsive and Have HER2 Expression
Led by RemeGen Co., Ltd. · Updated on 2023-07-13
85
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for participants with high-risk non-muscle-invasive bladder cancer NMIBC who either have not received BCG therapy or have not responded to it and are not suitable for or have declined radical bladder removal surgery. This study focuses on patients whose tumors express HER2 at levels of 1 or greater. The purpose is to assess the combination of RC48-ADC and gemcitabine in these specific patient groups to better understand its effects and disease control. Participants will be divided into two groups those who are BCG Nave and those who are BCG Unresponsive. All participants will receive intravenous RC48-ADC at 2.0 mgkg every two weeks for eight weeks, then every four weeks for up to forty weeks. Alongside this, gemcitabine will be administered intravesically once weekly for eight weeks during induction and then every four weeks for up to forty weeks during maintenance. After completing treatment phases, participants will enter a follow-up period for continued monitoring. During the study, participants will undergo regular assessments including imaging to confirm cancer status and safety monitoring. Researchers will measure outcomes such as 12-month disease-free survival, recurrence-free survival up to 24 months, and overall survival up to five years. Safety and disease progression will be carefully tracked throughout treatment and follow-up. Participants must comply with study procedures and follow-up visits, which will include physical exams, laboratory tests, and evaluations of heart and organ function.
CONDITIONS
Brief Title
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here